Eshelman Ventures, LLC — Full Portfolio
19 tracked investments · listed companies and verified rows first
Hyperion DeFi is a U.S.
BiotechCrypto & Web3FintechHealthtechLaguna Hills, US
Michael Rowe(Executive Officer, Director)Hyunsu Jung(Chief Executive Officer)inBARRY BUTLER(Executive Officer)David(Chief Financial Officer)TSONTCHO IANCHULEV(Executive Officer, Director)
BoardCURT LABELLE(Executive Officer, Director)
Board seatFred Eshelman· per SEC Form D · $8M raise · filed Aug 2016
Co-investorsTullis
Dignify Therapeutics develops "on demand" drugs that trigger emptying of the bladder and/or bowel when a person chooses, aimed at restoring control of bowel and bladder function.
BiotechDigital HealthMedical DevicesResearch Triangle Park, US
Edward C Burgard(Executive Officer, Director, Promoter)Karl Thor(Executive Officer, Director, Promoter)inBenny Ward(Executive Officer, Director, Promoter)in
BoardDaniel J Ricca(Director, Promoter)Ebrahim Versi(Director, Promoter)
Board seatFred Eshelman· per SEC Form D
Co-investorsRA Capital
BiotechDurham, US
Thomas Laundon(Executive Officer)William Moore(Executive Officer, Director)
BoardRichard Kent(Director)Kristopher Wood(Director)S. Edward Torres(Director)Steven Weinstein(Director)
Board seatFred Eshelman· per SEC Form D · $28.1M raise · filed Apr 2015
BiotechCharlottesville, US
John C. Herr(Executive Officer, Director, Promoter)Edward J. Leary(Executive Officer, Promoter)Brian A. Pollok(Executive Officer, Director, Promoter)
Board seatFred Eshelman· per SEC Form D · $3M raise · filed Feb 2015
Aruna Bio develops a proprietary neural exosome platform and a lead therapeutic neural cell-derived exosome, AB126, designed to cross the blood-brain barrier.
BiotechHealthtechAthens, US
Steven Stice(Chief Scientific Officer and Director)Harold W. Ingalls(Chief Financial Officer and Director)Tracey Stice(Chief Operating Officer and Secretary)
BoardJohn F. Mangan, Jr.(Director)C. William Griffin(Director)Russell C. Lindner(Director)
PartnerFred Eshelman· solo GP
Co-investorsEvolution VC PartnersGRA Venture
Breakthru operates a data platform with engagement tools designed to help brands connect with and build trust among young audiences.
Creator EconomyData & InfrastructureFintechMarketing TechSaaSLewes, US
Alex Miles(Founder & CEO)inGean Martinez(Co-Founder & CTO)in
Co-investorsOld Line Capital PartnersTechstars37 Angels
Breakthru is a drug development company that applies medicinal chemistry expertise to accelerate the discovery of breakthrough medicines, emphasizing data-driven decision-making about compound viability.
BiotechDeep TechHealthtech
PartnerFred Eshelman· solo GP
Carbon provides 3D printing hardware, photopolymer resins, and computational design software that brands use to design, develop, and manufacture high-performance products.
Advanced ManufacturingHardwareNew MaterialsRedwood City, US
Joseph M. DeSimone(Executive Officer, Director)inJoseph DeSimone, PhD(Co-Founder & Board Member)inPhilip DeSimone(Co-founder & Office of the CEO)inSteve Nelson(Launch CEO & Co-founder)inEd Samulski, PhD(Advisor & Co-founder)inAlex Ermoshkin, PhD(Co-founder)in
PartnerFred Eshelman· solo GP
Co-investorsSequoia CapitalBMW i VenturesFounders Circle CapitalG2 Venture PartnersNext Legacy PartnersSilver Lake Partners
Cavalry Biosciences is a biopharmaceutical company focused on developing medicines that leverage the body's inherent regenerative and repair mechanisms, particularly in areas of age-related disease and tissue regeneration.
BiotechDeep TechLongevityMedical Devices
Jan van Deursen, PhD(Co-founder, Advisor)inNathaniel (Ned) David, PhD(Co-founder, Chairman)in
PartnerFred Eshelman· solo GP
Co-investorsVenrockMission Biocapital
A biotech-focused investment firm that creates and backs companies in the future of medicine.
BiotechChattanooga, US
PartnerFred Eshelman· solo GP
Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2.
BiotechHealthtechDurham, US
Patrick Roberts(Executive Officer and member of the Board of Managers.)in
BoardFredric N. Eshelman(Executive Officer and member of the Board of Managers.)Sid Subramony(Member of the Board of Managers.)Norman Sharpless(Member of the Board of Managers.)
PartnerFred Eshelman· solo GP
Co-investorsCape Fear BioCapitalHatteras Venture PartnersHatteras
Jupiter is a biotech company that discovers and develops new medicines across multiple therapeutic areas.
BiotechChapel Hill, US
Ned Sharpless(Co-founder & CEO)Leigh Delacy(Co-founder & Partner and COO)
PartnerFred Eshelman· solo GP
Co-investorsMission Biocapital3one4 CapitalBEENEXTHummingbird VenturesLB InvestmentPeak XV Partners+2 more
KOMO Biosciences develops genome engineering technology based on hyperactive large serine integrases to transform cell-based manufacturing of biologics and advanced therapies.
BiotechDeep Tech
Jennifer Manning(Founder & CEO)inThomas Page(Acting CTO)inMatt Farabaugh(Acting CFO)Jesse B. Owens(Acting CSA)in
BoardRay Tabibiazar(Chairman of the Board)
PartnerFred Eshelman· solo GP
Co-investorsGenesis BioCapitalModi VenturesGENERAL INCEPTIONLDV Partners
Company working with governments, international agencies, and private partners to improve access to medicine across Sub-Saharan Africa, spanning product development, manufacturing, supply chains, and patient delivery.
PartnerFred Eshelman· solo GP
Paradigm Therapeutics is a biopharmaceutical company developing Zorblesia (SD-101), a proprietary topical whole-body therapy for treating the wounds, lesions, and infections associated with all subtypes of Epidermolysis Bullosa (EB), a rare genetic connective tissue disorder.
BiotechHealthtechMedical DevicesMt Pleasant, US
Robert Ryan(Dr.)
PartnerFred Eshelman· solo GP
Phoenix Molecular Designs (PhoenixMD) is a biotechnology company developing targeted breast cancer therapeutics, including PMD-026, a first-in-class RSK2 inhibitor in Phase 2 clinical trials paired with a companion diagnostic.
BiotechDeep TechHealthtech
Sandra Dunn(Founder)inJoseph Leveque(Chief Medical Officer)Aarthi Jayanthan(Chief Operating Officer & Chief Scientific Officer)inMichael Liggett(Chief Financial Officer)Martin S. Olivo(Chief Development Officer)Joe Ninosky(Chief CMC Officer)
PartnerFred Eshelman· solo GP
Co-investorsFlucas VenturesPallasite Ventures
BiotechScarsdale, US
Barry Kappel, Ph.D.(Executive Officer, Director)
BoardIsaac Blech(Director)Robert Ruffolo, Ph.D.(Director)David Scheinberg, Ph.D.(Director)
PartnerFred Eshelman· solo GP
Co-investorsConnectivity Ventures
Wilmington Design Company (WDC) is a full-service marketing agency offering custom website design and development, brand identity and logo design, SEO, paid advertising, and digital marketing strategy for small businesses.
AdTechMarketing TechWilmington, US
PartnerFred Eshelman· solo GP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.